A3P Switzerland
Aseptic Process & Low Bioburden
INTRODUCTION
Aseptic and Low Bioburden Processes : Control, Innovation and Compliance with Annex 1
📅 March 3–4, 2026
đź“Ť Beau-Rivage Palace, Lausanne (Switzerland)
The EU GMP Annex 1 places contamination control and aseptic process performance at the forefront of pharmaceutical manufacturing priorities. The A3P Congress 2026 will dedicate two full days to aseptic and low bioburden processes, bringing together experts, industry leaders and regulatory representatives to discuss compliance, innovation and operational excellence.
Key topics will include:
- Aseptic Process Simulation (APS): validation strategies, best practices and case studies.
- Process Improvement: new technologies, automation and risk management to ensure robustness and consistency.
- Environmental Control: monitoring strategies and contamination control for both particulate and microbiological aspects.